reported that three human cases of H9N2 infections have been identified in China from September 27, 2016 , to February 27, 2017 Its occasional transmission to humans has raised the possibility of a damaging pandemic spreading through an immunologically naive population. 9, 10 The conventional production of avian influenza vaccines is complicated by the need for a large number of embryonated chicken eggs and disposal facilities. Studies of virus-like particles (VLPs) in animals and humans indicate that an influenza vaccine platform designed to present both full-length HA and NA antigens in VLP form may better emulate native presentation of these antigens to the immune system, yet at the same time avoid the safety concerns posed by a live, replicating agent. 11 Moreover, it was reported that the heterologous coexpression of the H3N2 genes HA, NA, M1, and M2 in insect cells has been shown to result in the self-assembly of VLPs, which act protectively against H3N2 in mice. 12, 13 The development of an H9N2
influenza VLP vaccine effective in BALB/c mice requires the expression of only three viral proteins, namely HA, NA, and M1. 14 Thus, VLPs which resemble infectious virus particles with respect to structure and morphology have been suggested as novel vaccine candidates against various viral infections. 15 Live poultry markets and farms in Shanghai have been under surveillance since 2006; during this time, H9N2 has been detected in both poultry and swine. The co-circulation of multiple H9N2 genotypes over the past decade has led to the emergence of the G57 genotype, which displays a changed antigenicity and improved adaptability in chickens. 16 It has become predominant in vaccinated farm chickens in China, causing widespread influenza outbreaks before the H7N9 viruses emerged in humans; the latter viruses have inherited their internal genes from G57 genotype strains. In a previous study, the immunity efficacy of the currently used vaccine (A/chicken/shanghai/F/1998) against H9N2 has been evaluated and found unable to provide complete vaccine protection. 17 Here, the HA and NA genes from a strain belonging to G57 genotype were used to construct a potential VLP-based vaccine to protect against H9N2.
| MATERIALS AND METHODS

| Ethics statement
The conduct of this study followed animal welfare guidelines set out were cloned into the pFastBac™ dual vector (Invitrogen, Waltham, MA, USA). The HA and NA sequences were found to be identical to those deposited in GenBank (respectively, KU720440 and KU720446).
| Generation of recombinant baculoviruses
The 
| Production of H9N2 VLP and preparation of VLP vaccine
The rescued recombinant baculovirus was propagated and titered When HI titers to homologous virus reached 2 8 -2 10 , blood from the four chickens was mixed. H9N2-specific serum (A/chicken/ Shanghai/06/2015) was inactivated at 60°C for 10 minutes and stored at −30°C until use.
As the VLP antigen used was not sucrose-purified (to reduce production costs), its antigen content was quantified in terms of hemagglutination units (HAU) as described in the OIE manual, 18 rather than by measuring the total protein concentration. 19 
| Electron microscopy
The culture medium containing VLPs was treated for 24 hour at 4°C with 2% glutaraldehyde in phosphate-buffered saline (PBS) (pH 7.2), adsorbed on a freshly discharged plastic/carbon-coated grid, which was then rinsed in deionized water (East China Normal University, Shanghai, China). The grids were finally stained with 2% sodium phosphotungstate (pH 6.5), and the VLPs were observed by transmission electron microscopy at a magnification of 6000-100 000×.
| Neuraminidase assay
Neuraminidase activity was determined using a Neuraminidase Assay Kit (Sigma), according to the supplier's protocol.
| Vaccination and challenge
A group of 15 three-week-old SPF chickens was divided into three 
| Statistical analysis
Statistical comparisons between vaccinated and nonvaccinated chickens were performed using Fisher's exact test. An analysis of variance using the Tukey-Kramer post-test was used to compare virus shedding titers. Statistical significance was assigned to differences applying a P-value threshold of .05. 
| RESULTS
| Expression of VLP vaccine for influenza
| The immune response to the H9N2 VLPs
After the second (boost) vaccination, the commercial H9N2 whole- (Table 1 ). There was no detectable induction of antibody in chickens which had received a mock vaccination (PBS/adjuvant). Thus, the VLP vaccine was able to induce a better H9N2-specific functional antibody response to the recent H9N2 strain than currently used commercial vaccine. No virus was detectable in the cloacal swabs.
Virus was present in the tracheal swabs of both nonvaccinated and vaccinated chickens at 1, 2, 3, and 5 dpc (Figure 3) . No virus was detected in all tracheal swabs at 7 dpc. Less viruses were shed by VLP-immunized subgroup among the three subgroups. On 2 and 3 dpc, statistically significant differences (P < .05) were noted in the amount of shedding virus between VLP-immunized subgroup and the other two subgroups, but no statistically significant differences (P < .05) existed among the other two subgroups. As a result, VLP vaccine can prevent the shedding of H9N2 influenza virus moderately, compared to currently used commercial vaccine.
| DISCUSSION
In China, an inactivated H9N2 subtype influenza virus vaccine (A/ Chicken/Shandong/6/1996) was approved for prevention of H9N2 influenza virus infections in 1998. Since then, monovalent and combined vaccines have been seen on the market. 21 Although there are other commercial vaccines used in poultry farms against H9N2 viruses in China, all the vaccines were inactivated virus. To note, the isolation time of these seed strains was from 1994 to 2005. 22 However, H9N2 influenza virus is evolving by reassortment and mutation and so on.
Most recently, Pu et al 16 revealed that G57 had become the predominant H9N2 genotype in chicken population. Importantly, the G57 viruses have developed the ability to escape from immunization with changed antigenicity and improved fitness. Furthermore, our study also showed that antigenic groups typically correspond with the phylogenetic relationships between viruses and that currently used commercial vaccine provides a reduced level of protection against more recent H9N2 strains. 17 Thus, this underlines the need for updating the vaccine used to give protection against current strains.
Although the first cell-based and recombinant subunit influenza vaccines have been introduced and approved by the regulatory agencies, the majority of influenza vaccines are still made in eggs, and if there is an outbreak of avian influenza or other disease that affects chicken flocks, the supply of vaccine could be threatened. 23, 24 Moreover, cost is also one of the major impediments to the more widespread use of vaccination in poultry production. An advantage of the VLP approach is that it can respond rapidly to the development of new strains of the virus. It was reported that influenza virus hemagglutinin (HA) and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived VLPs. 25 In our study, we chose HA and NA to construct VLP. Consistent with reported data, our results demonstrated that the formation of VLP was alike to the influenza virus particles under electron microscopy. Other studies suggested that detected broader reactivity in baculovirus-derived VLP vaccines containing M1. [26] [27] [28] The protection of VLP including HA, NA, and M1 needs to be further investigated.
Furthermore, the supernatant, without concentration, which had an HA titer of 2 6 generated by VLPs, is sufficient to induce a higher response at the site of inoculation, which may be responsible for the enhanced immunogenicity of VLP vaccination in poultry. 33 According to this character, our baculovirus-expressed influenza VLP antigen was elaborated without extensive purification: all that was required was to include a low-speed centrifugation step in order to remove large cell debris. To note, our results showed that no inflammation or other adverse events were observed at the sites of injection in our research.
In summary, these results indicate that nonreplicating influenza VLPs represent a promising strategy for the development of a safe and effective vaccine to prevent and control H9N2 influenza viruses.
